AB-BIOTICS’ AB21® and LipiGO® winners of the NutraIngredients Awards

19 May 2022 – 2 min read

We are thrilled to announce that our two finalists, AB21® and LipiGO®, have both taken home the crown in their respective categories for this year’s NutraIngredients Awards.

Following on from our win in 2015, we couldn’t be happier to see our hard work recognised. With so many great entries, and a record number of them this year, it’s an honour to have not only been shortlisted but to take home two wins – a great achievement for everyone here at AB-BIOTICS.

Photo – AB21® strains modulate the adaptive immune response to a viral infection

AB21® is a unique combination of bacterial strains shown to reduce symptoms of viral infection and that can be used to potentiate immunity after vaccination. Created in 2020 in response to the unpredictable pandemic, it is the first probiotic validated through rigorous randomized, placebo-controlled clinical trial for the treatment of SARS-CoV-2 infection. When the rate of infection quickly accelerated, our talented researchers, scientists and NPD teams acted fast in coming up with a natural product to support consumers’ immunity during this difficult time. As our quickest developed probiotic in the range, we’re proud that AB21® is already being recognised for its high quality and functionality in such a competitive industry.

What the judges said: It’s the year when protection from the coronavirus vaccines is fading, whilst the number of long covid cases are rising. Judges believe AB21 could be a real game changer and the ambassador for the probiotic category, based on the convincing clinical data in covid patients shown to reduce symptoms of viral infections and potentiate immunity after vaccination.

LipiGO® was developed over a period of 12 years with consumers’ long-term gains in mind. The awareness of postbiotics is quickly catching up to that of probiotics and as we know, they are equally important. With consumers becoming more health conscious over the last two years, post-pandemic, we don’t expect the growth of postbiotics to slow down and we are dedicated to spreading awareness of their importance. Parallel to this, the clean label trend is driving consumers to seek out products which are produced in a more natural way and/or contain more recognisable ingredients. With LipiGO®, consumers can have peace of mind as their postbiotic is extracted from yeast and is clinically proven to ensure a successful and safe weight loss while maintaining the ideal body weight without risks of rebound.

What the judges said: Maintaining the achieved weight loss over long term is a though challenge for those who diet. LipiGO’s well documented properties demonstrated not only weight loss, but also a prevention of weight regains after one year. Judges found these properties to possess the winning X-factor! 

Photo – LipiGO® is extracted from the yeast Saccharomyces cerevisiae 

The future looks bright

Overall, the 2022 NutraIngredients Awards were a roaring success and we’re thrilled to have been a part of it. The team in Barcelona gathered to watch the winning announcements and the atmosphere was nothing short of amazing following two wins! We’d like to thank the judges for recognising AB21® and LipiGO® as stand out innovations in the nutraceuticals industry and congratulate those who entered, it was a tough competition! We can’t wait for next year’s awards – stay tuned.  

To learn more about our full range of pro and postbiotics, visit our website or get in touch today.